TO:
Board of Directors
International Society for Pharmacoeconomics and Outcomes Research
505 Lawrence Square Blvd South
Lawrenceville, NJ 08648 USA

PREPARED BY:
Joanna Lis, MSc, PhD
Department of Pharmacoeconomics of Medical University of Warsaw and Sanofi Group
Warsaw, Poland
Tel: +48 607370093
Email: joanna.lis@sanofi.com

Background:
The ISPOR Poland Regional Chapter was established in July 2000. The Chapter consists of 170 members.

The Board of the ISPOR Poland Regional Chapter is comprised of the main functions:

President  Joanna Lis, PhD, Assistant Professor
Department of Pharmacoeconomics of Medical University of Warsaw, Warsaw, Poland

President-Elect  Maciej Niewada, MD, Professor
Department of Clinical & Experimental Pharmacology of Medical University of Warsaw,
Warsaw, Poland

Past-President  Karina Jahnz-Różyk, MD, Professor
Head of Department of Immunology & Allergology
Military Institute of Medicine,
Warsaw, Poland

Secretary  Marcin Czech, MD, Professor
Department of Pharmacoeconomics of Medical University of Warsaw,
Warsaw, Poland

Treasurer  Witold Owczarek, MD, Professor
Department of Dermatology of Military Institute of Medicine,
Warsaw, Poland
For more information on the ISPOR Poland Chapter, please visit the ISPOR Regional Chapter website at http://www.ispor.org/regional_chapters/poland/index.asp and www.farmakoekonomika.pl.


**ISPOR Poland Chapter Annual Report 2013**

<table>
<thead>
<tr>
<th>Activities / Accomplishments</th>
<th>Summary</th>
</tr>
</thead>
</table>
| **Scientific / Educational Activities**               | • 15\textsuperscript{th} Warsaw Days of Cardiology/ 3\textsuperscript{th} Summer Meeting of cardiovascular Pharmacotherapy Session of Polish Society of Cardiology and Polish Pharmacoeconomic Society - 6\textsuperscript{th} June 2013, Warsaw  
  Topics of ISPOR Chapter Members lectures:  
  ➢ Costs of heart failure in Poland - M.Czech  
  ➢ Risk-sharing instruments - cases of cardiology medications - J.Lis  
  ➢ Biological drugs in Poland - K.Jahnz-Różyk  
  ➢ QALY - ‘for and even against’ - M.Niewada  
  • Educational session led by J. Lis: ‘The role of non-experimental studies in medical decision process during the 8\textsuperscript{th} International Evidence Based Health Care Symposium “HTA & Efficient Management of Basic Benefit Package”, 7-8 October 2013, Warsaw.  
  Topics of lectures during the Poland ISPOR Chapter session:  
  ➢ Are non-experimental researches necessary? Researches of IV phase in obstructive diseases - K.Jahnz-Różyk  
  ➢ Statistical methods in analysis of observational data -M.Górkiewicz  
  ➢ The study of causality in non-experimental data - M.Jakubczyk  
  • Development of 4 scientific sections from members of Polish Society of Pharmacoeconomics, which work on specific topics:  
  ➢ Health Technology Assessment  
  ➢ Health-related quality of life  
  ➢ Therapeutic programs, Pharmaceutical Care and Pharmaceutical Law  
  ➢ Epidemiology and cost of illnesses  
  HRQoL Special Interest Group of ISPOR Poland Chapter is working on:  
  *Methodology and development of the Polish Dictionary of Quality of Life Term.*  
  • Working on the translation of ISPOR book into Polish language:  
    *Therapeutic and Diagnostic Device Outcomes Research*
Two publications in ISPOR ViHRI:
- “What Influences Recommendations Issued by the Agency for Health Technology Assessment in Poland? A Glimpse Into Decision Makers’ Preferences”
- “Costs of Medically Attended Acute Gastrointestinal Infections: The Polish Prospective Healthcare Utilization Survey”

Continuing development of the regional journal on health economics: “Journal of Health Policy and Outcomes Research (JHPOR)” issued under the auspices of the Polish Society of Pharmacoeconomics
- two issues of the JHPOR magazine were published in 2013
- JHPOR obtained Index Copernicus = 5.3 points.

Organization of competition for the best scientific work in the field of pharmacoeconomics in Poland (8th edition) - awarded during 11th International Conference of ISPOR Poland Chapter: Warsaw, 5-6 December 2013

ISPOR Chapters Members’ scientific activities in 2013
- Scientific and educational papers: 17
- Lectures/debates and posters: 25

Policy-Related Activities

Working with ISPOR Central & Eastern Europe Network (CEE Network) – active participation in:
- ISPOR CEE Network Executive Committee
- ISPOR CEE Network Education Committee
- ISPOR CEE Network Publication Committee
- ISPOR CEE Network Research Committee

Establishment of a close co-operation with ISPOR Russia and Ukraine Chapters:
- Prepare the Forum based article to ISPOR CEE Network Newsletter: “The Use of Pharmacoeconomic Principles in Local Drug Policy Decisions in Poland”

Cooperation with INFARMA (the Employers’ Union of Innovative Pharmaceutical Companies, a member of the European Federation of the Pharmaceutical Industries and Associations (EFPIA)) regarding a biological drugs situation in Poland.

Working with the Polish authorities on updates of the Pricing & Reimbursement Bill in Poland:
- Meetings with representatives of the Health Authorities
### Conferences and/or Chapter Meetings

<table>
<thead>
<tr>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
</table>
| **ISPOR CEE Network Forum: ‘Pricing of Pharmaceuticals in Emerging Countries of the Central and Eastern European Region’ - New Orleans, 21st May 2013.** | Discussed issues:  
  ➢ The application of the pharmaceutical price arsenal in some emerging countries of Central and Eastern Europe.  
  ➢ Presentation of preliminary findings of a Central and Eastern European policy survey on the implications of international pharmaceutical price referencing.  
  ➢ The Polish Pharmacoeconomic Society was represented by Joanna Lis, President of ISPOR Poland Chapter. |
| **5th Polish-Russian Forum, Moscow, 4-5 June 2013**                   | The Forum was divided into two topics:  
  ➢ Pharmacoeconomics and reimbursement  
  ➢ Registration and market access  
  Among the topics of lectures dominated legal issues governing the registration of drugs, medicines management and health insurance aspects of economic evaluation in the health sector with a focus on health technology assessment (HTA) in the system, the importance of indirect costs and the role of a quality adjusted life years (QALY) as the therapy affects measure.  
  From medical specialties point of view illustrated and discussed aspects of rare diseases, including cystic fibrosis, as well as challenges in treating lifestyle diseases such as diabetes, heart failure or psoriasis. Most of the conference was devoted into issues of pricing, risk-sharing instruments, clinical trials and the role of HTA in Europe and Russia. |
| **ISPOR CEE Network Forum: ‘The use of Pharmacoeconomic principles in local drug policy decisions in Poland, Russia and Ukraine’, Dublin, Ireland, 2-6 November 2013** | The forum discussed changes in drug policy decisions in Poland, Russia and Ukraine with particular focus on the use of pharmacoeconomic principles in local policy decisions. Speakers (PPS represented Joanna Lis and Karina Jahnz-Róży) described how these principles have been applied for effective formulary management, individual patient treatment and resource allocation. |
| **11th International Conference of ISPOR Poland Chapter: Warsaw, Poland,  5-6 December 2013** | Title: *Current trends in reimbursement and pricing of medicines in Europe.* |
Around 300 participants including 7 foreign speakers, representatives of polish health care authorities and experts took part in the conference.

The congress began with pre-conference expert meeting with participation of members of the Transparency Agency for Health Technology Assessment in Poland (AHTAPol): “Achievements and Dilemmas of Transparency Council”. The experience of members of the Transparency Council, the challenges of the current regulations and rules of health technology assessment were put before the Council. The session brought together representatives of the National Health Fund, the Office for Registration of Medicinal Products and the Patient Ombudsman.

The conference was opened with the plenary session entitled "Current issues in pricing and reimbursement from the perspective of the leading European HTA Agencies & Health Authorities," in which European experts working with institutions such as NICE, HAS, AMNOG, AHTAPol. The HTA representatives’ areas of interest presented current trends in health technology assessment from the perspective of their countries and agencies.

The second day of the conference began with a multidisciplinary session entitled "Economic challenges in the medical specialties". The main issues in health economics in different fields of medicine were presented. National consultants, presidents of scientific societies in various fields of medicine participated the discussion.

Session on "Economic evaluation of the effectiveness of anticancer therapy - the nature and challenges of measuring the health benefits in oncology." We assessed the measure of QALYs in determining the true value of health benefits obtained under the influence of anti-cancer treatment to the legislative changes introduced in Poland. Comparison and variety of solutions for the economic evaluation of anticancer drugs, which are used in the reimbursement systems of Polish, UK, Canada, Australia and Germany were presented.

Two sessions of “indirect costs in the healthcare system in Poland and the world” were also held.

First session entitled “Indirect costs in the healthcare system in Poland and in the world” described the methodology for measuring indirect costs in the Polish health care system. Indirect costs of cancer in Poland, Europe and the world were also presented.

Second session entitled "The challenge in the analysis of HTA-related costs - direct and indirect" presented the quality of costing data and cost-effectiveness of health technologies.

The conference ended with poster session. Overview of work on the practical aspects of economic evaluation in different types of disease, and the role of non-experimental studies in decision-making in health care and other issues
relevant to pharamacoconomics and HTA were presented.

- Detailed agenda and conference report are enclosed as appendix.

<table>
<thead>
<tr>
<th>Membership Development</th>
<th>44 new members in 2013 (from 126 to 170 – an increase of 35% )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other</td>
<td>A new website of Polish Pharmacoeconomic Society at: <a href="http://www.farmakoekonomika.pl">www.farmakoekonomika.pl</a> was created. The website has new functions to assure safe, user-friendly and high-level medium to contact with Polish Pharmacoeconomic Society Members.</td>
</tr>
</tbody>
</table>

### Upcoming Activities for ISPOR Poland Chapter 2014

<table>
<thead>
<tr>
<th>Date</th>
<th>Activities</th>
</tr>
</thead>
</table>
| May - June      | Active participation ISPOR 19th Annual International Meeting, May 31- June 4, 2014  
                                Palais des Congrès de Montréal, Montreal, QC, Canada |
| November        | Active participation ISPOR 17th Annual European Congress, 8-12 November 2014  
                                Amsterdam RAI, Amsterdam, The Netherlands |
| Q4/2014         | Publication of the Polish edition of the ISPOR books:  
                                1. Therapeutic and Diagnostic Device Outcomes Research  
                                2. ISPOR Taxonomy of Patient Registries: Classification, Characteristics and Terms. |
| December        | Organization of 12th ISPOR Poland Chapter Conference in Warsaw |
| All year around | Publications in Value in Health Regional Issues (VIHRI), focusing on CEEWA |
| All year around | Monthly regional chapter’s sections meetings, debates on current health outcomes/HTA issues |
| All year around | Cooperation with ISPOR, particularly developing close contacts with ISPOR Central and Eastern European Chapters (ISPOR CEE Network)  
                                Active involvement in CEE Network initiatives |
| All year around | Pre-preparation to 19th Annual European Congress, November 2016, Warsaw, Poland |